Seven Fleet Capital Management LP Acquires 14,771 Shares of Axsome Therapeutics, Inc. $AXSM

Seven Fleet Capital Management LP boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 105.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,826 shares of the company’s stock after acquiring an additional 14,771 shares during the period. Axsome Therapeutics accounts for approximately 1.2% of Seven Fleet Capital Management LP’s holdings, making the stock its 19th biggest holding. Seven Fleet Capital Management LP’s holdings in Axsome Therapeutics were worth $7,056,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Axsome Therapeutics by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after acquiring an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after purchasing an additional 7,320 shares during the period. Goldman Sachs Group Inc. raised its holdings in Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after purchasing an additional 84,151 shares in the last quarter. Caxton Associates LLP bought a new position in Axsome Therapeutics in the first quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.8%

Axsome Therapeutics stock opened at $206.68 on Friday. Axsome Therapeutics, Inc. has a one year low of $112.90 and a one year high of $260.19. The business’s fifty day moving average is $223.81 and its 200 day moving average is $207.48. The stock has a market capitalization of $10.83 billion, a PE ratio of -55.11 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The company had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. On average, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Mark Coleman sold 643 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total value of $160,107.00. Following the sale, the director owned 30,389 shares of the company’s stock, valued at $7,566,861. The trade was a 2.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Susan Mahony sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the sale, the director directly owned 1,129 shares in the company, valued at $267,810.09. The trade was a 20.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 193,229 shares of company stock worth $44,752,676 in the last 90 days. 20.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Friday, July 17th. TD Cowen lifted their price target on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. UBS Group reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Monday, August 24th. Guggenheim upped their price objective on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Mizuho upped their price objective on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $267.60.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.